Human islet function is not impaired by the sphingosine-1-phosphate receptor modulator FTY720

Area of Science:

• Immunology
• Endocrinology
• Pharmacology

Background:

• Clinical islet transplantation for type 1 diabetes mellitus (T1DM) is limited by toxic immunosuppressants.
• Sphingosine-1-phosphate receptor (S1PR) modulators are effective in autoimmune diseases.
• The potential of S1PR modulators in islet transplantation requires investigation.

Purpose of the Study:

• To evaluate the effects of FTY720 on human islet function and survival.
• To assess FTY720's impact on glucose-stimulated insulin secretion and apoptosis in vitro.
• To examine FTY720's effects on islet graft function in vivo.

Main Methods:

• Human islets were exposed to FTY720 in vitro to assess insulin secretion and apoptosis.
• Islets were transplanted into immunodeficient mice with chemically induced diabetes.
• In vivo assessment included blood glucose, oral glucose tolerance tests, and C-peptide levels over 50 days.

Main Results:

• FTY720 exposure did not impair human islet function in vitro.
• In vivo, FTY720 did not negatively affect transplanted islet function.
• No detrimental effects on glucose metabolism or insulin secretion were observed.

Conclusions:

• FTY720 demonstrates no adverse effects on human islet function.
• Emerging S1PR modulators may be beneficial for clinical islet transplantation.
• These compounds offer potential immunological protection without diabetogenicity.